INTRODUCTION
Medical research delivers large health, social and economic benefits. 1 As countries continue to invest in health, global investment in medical research continues to climb, especially in high-income countries. 2 Disproportionate amounts of research funding are spent on: (1) conditions with relevance in high-income countries even though the disease burden is greater in low-income countries 2 and (2) prevalent and costly public health problems secure government funding priorities in preference to rarer diseases. Philanthropic funding for global research is crucial, 3 and the important role of research patient organisations has been recognised for brain disorders in Canada 4 and rare diseases in Australia. 5 In the USA, the independent organisation Patient-Centered Outcomes Research Institute (PCORI) provides funding for patient-focused research that encourage collaborations across sectors to provide benefit directly to patients, including new projects in 2016 for people and families living with CP.
CP is the most common childhood physical disability with a prevalence of 3.1 per 1000 births in four areas of the USA, 6 compared with 2.1 per 1000 live births in Australia. 7 In the last 10 years, the Australian rate has decreased from 1-in-526 births to 1-in-625 births, alongside reductions in co-occurring
Strengths and limitations of this study
▪ This study examines the current state of philanthropic and competitive funding for cerebral palsy (CP) research in Australia, and the direction that competitive funding for CP research is moving in relation to National Institutes of Health (NIH) funding in the USA. ▪ In Australia, the analysis of funding from National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC) is limited by the public availability of summary spreadsheets and final project summaries and the specific ARC exclusion of medical and clinical research. ▪ The findings are an underestimate of CP funding as the search for grants was based on strict keyword searches, and the comparison between Australia and the USA is limited to competitive grants (NHMRC and NIH). The analysis is also limited due to the exclusion of other philanthropic or charitable organisations in Australia and the USA.
epilepsy (20% reduction), intellectual disability (17%) and wheelchair use (15%). 8 These reductions are evidence of the cumulative translation of research findings from projects that started with CP funding.
Additional research impacts include reducing the collective economic costs of CP on the Australian community, estimated in 2007 to be almost $4 billion annually.
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In Australia, people living with CP and their families have clearly articulated prevention and cure of CP as their highest priorities for future research as identified by a Delphi study. 10 Yet the public and health professionals' perception regarding CP has historically been a disability that cannot be prevented or cured, and so the research has focused on interventions aimed at improving quality of life. A key role for CP researchers and CP advocates worldwide is to challenge these public perceptions. 8 Prevention and cure may include a reduction in CP severity where people are mobile and do not require a wheelchair or no longer have epilepsy.
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The aim of this study is to examine the current state of philanthropic and competitive funding for CP research in Australia, and the direction that competitive funding for CP research is moving in relation to the USA. In the past decade, the focus of Australian CP research has expanded from interventions and therapies, to prevention and cure of CP. In comparison with the NIH funding for CP research, 12 13 Australia has a smaller yet growing community of CP researchers seeking funding. This study will examine the funding for CP research in Australia from the single philanthropic funding body specifically for CP research and the major competitive funding schemes from the government. It will examine: (1) whether CP funding is increasing in real terms; (2) whether CP funding in Australia is increasing compared with the NIH and (3) the Australian community of CP researchers and how these networks have interacted to successfully obtain funding.
METHOD
To obtain a complete picture of competitive and philanthropic funding of CP research in Australia, information was sought from Cerebral Palsy Alliance (CPA), NHMRC and ARC. 15 The Australian Government provides competitive grant funding through: (1) NHMRC as the major funding body for health and medical research; and (2) ARC funds research and innovation, including industry partnerships, specifically excluding medical, clinical or dental research. In the past decade, and relative to NHMRC and ARC, CPARF is the new funding scheme that is specifically for CP research.
Funding bodies

Funding type
Cerebral Palsy Alliance Research Foundation (CPARF) Total CPARF funding was categorised as: (1) people and infrastructure; (2) strategic grants to pursue prevention and cure and (3) competitive grants. 15 The CPARF competitive grants programme is administered through a formal application process including external peer review. The research priorities for the programme are prevention and cure of CP, and novel interventions. NHMRC inclusion/exclusion criteria: We extracted CP-related grants from the complete list of NHMRC grants by searching for the keywords 'cerebral' and 'palsy', or the phrase 'neonatal encephalopathy' in the final reports. The absence of these keywords/phrase in the NHMRC data excluded grants that may be known to benefit CP research, resulting in an underestimate of total CP funding. For the 2015 NHMRC data, only the lead researcher was listed in the public domain and no data were available on the funding breakdown by year, so we assumed the total income was spread equally over the (future) funded years.
NHMRC final reports were available for 2004-2012 only; the datasets were publicly accessible from the NHMRC website in 2015. The search of the final reports uncovered projects that were only partly related to CP, for example, CP was referred to as a potential consequence but was not the main aim; these projects were excluded from the analysis. For grants that were not solely dedicated to CP a fraction of funding was used, for example, CP was one of four conditions mentioned in the final report, the total funding amount was divided by four and that quarter amount was included in the analysis. These were crude adjustments, but avoided overestimating the total funding for CP research. Clinical trials that were not solely focused on CP, or may have translated to CP in the future, were excluded. Additional NHMRC spreadsheets were searched for funding allocations by health condition or disease; this data is a combination of information provided by the researchers in their original applications and subjective determinations by internal NHMRC processes. 16 Australian Research Council (ARC) ARC competitive grant schemes for People (Future Fellowship) and Projects (Discovery and Linkage) specifically exclude medical, clinical and dental research that examines the understanding or treatment of a health condition or disease. 18 ARC funded projects from 2004 to 2015 were searched for the keywords 'cerebral' and 'palsy'; the medical phrase 'neonatal encephalopathy' was not used, given the ARC exclusion of medical research. Grants using the keyword 'disability', and not specifically 'cerebral palsy' were excluded. 12 The NIH funding is shown in this study as the combined total amount, and in terms of award year rather than expenditure year.
Funding trends
Plots for funding trends are expenditure over time. There are two ways of displaying funding over time: (1) by the year the grant was awarded and (2) by the year of expenditure. Our preference is to show the results by expenditure year as this is a better reflection of overall research activity. For the 2015 NHMRC grants where the annual expenditure was unavailable, the total amount was spread evenly over the years of the project. For example, a project with a total budget of $300 000 running from 2015 to 2017 would have $100 000 in each year. Annual totals were used to show the overall levels of expected research activity over time.
Annual funding figures were adjusted for inflation using the Australian consumer price index (US index for NIH data), which reflects the historic change in purchasing power over time. 19 We compared the similarity in trends over time using time series plots, calculated the Pearson correlation between the three funding agencies and used linear regression to look for a statistical increase in funding over time. All analyses were completed using R V. 
Network analysis
The network analysis examined the links between researchers who won funding from CPARF or NHMRC. If two researchers were investigators on the same grant they are linked in the network diagram. Researchers were anonymised by number ranking according to their overall income from the respective funding body, with the 'number 1' assigned to the highest funding earner.
The 'igraph' library in R was used to produce networks for CPA or NHMRC funding.
RESULTS
CPARF funding
The total CPARF philanthropic funding for CP research in Australia NHMRC funding by health condition From 2000 to 2014, NHMRC funding for CP research increased in real terms (figure 2). From the NHMRC database for disease and health issues, 16 CP funding is comparable with other related health conditions: (1) CP and autism are included under developmental disorders and disability; (2) CP and Parkinson's disease are included under nervous system (Neuroscience) disorders; and (3) cystic fibrosis and childhood diabetes are comparable with CP as they are also a lifelong condition diagnosed in childhood.
In 2012, the NHMRC funding for all people living with the respective condition was: AU$2.2 million for CP; AU$4.3 million for autism; AU$3.3 million for cystic fibrosis; AU$7.7 million for Parkinson's disease and AU $6.3 million for childhood diabetes. 16 For an individual person living with the respective condition, this equated to NHMRC funding of: AU$64 for CP; AU$67 for autism; AU$1046 for cystic fibrosis; AU$154 for Parkinson's disease and AU$1097 for childhood diabetes. In comparison, NIH funding in 2014 for an individual person living with the condition equated to US$27 for CP, US$53 for autism and US$2566 for cystic fibrosis.
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Competitive grants
The funding for CP research in Australia (2000 Australia ( -2015 is compared between the philanthropic CPARF, and the major government funding bodies NHMRC and ARC ( figure 3) . From 2005 to 2015, the CPARF funded 102 grants: People (n=27) and Project (n=75). The total amount spent on competitive grants was $10 645 900 (in 2015 dollars after adjustment for inflation is $11 209 557). There was relatively large variability in funding over time. In 2011 and 2012, the funding levels dipped, but increased greatly from 2013 to 2015. The CPARF average total amount invested per year was $878 094.
From 2000 to 2015, the NHMRC funded 125 grants for CP research, as identified from the spreadsheets (n=105), final reports (n=2) or both (n=18); and summarised into People (n=51), Project (n=67) or Centre (n=7). The total NHMRC funding spent on CP research was $53 533 966 (in 2015 dollars after adjustment for inflation is $63 035 914). Six ARC grants were related to CP research and included the areas of citizenship and independent living: People (n=1) and Project (n=5). The ARC total amount spent on CP research was $1 541 956 (in 2015 dollars after adjustment for inflation is $1 706 647). Due to the low number of ARC grants for CP research, the analysis is limited for any comparisons with CPARF or NHMRC.
NHMRC and CPARF sources of competitive funding show a general upward trend in funding with some boom years ( figure 3) . The large correlation between the NHMRC and CPARF (r=0.84, p=0.002) is partly driven by the steady rise over time for both funding agencies. For comparison purposes, figure 3 includes the total funding awarded from the CPARF (total from figure 1 ) and the total NHMRC funding for CP as the target health condition nominated by CP researchers in their original applications (total from figure 2, $26 million from 2000 to 2015). This analysis identified far more CP funding by the NHMRC ($53.5 million) compared with the data set prepared by the NHMRC based specifically on health conditions nominated by the researchers; a difference of over $27 million in identified grants.
Comparison with NIH
The NIH funding is shown in terms of award year rather than expenditure year as provided by Wu et al.
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Funding for CP in the USA has greatly increased in real terms (figure 4). The mean increase in funding per year was: $105 000 for NHMRC funding, $184 000 for CPARF funding and US$ $4.9 million per year for NIH funding. The increase in funding over time was statistically significant for the NIH (mean $4.9million, 95% CI 3.6M to 6.2M, p<0.001), but not for the NHMRC (mean $104K, 95% CI −77K to 287K, p=0.2) and CPARF (mean $184K, 95% CI −10K to 379K, p=0.06).
In the USA, funding for CP has also increased in terms of the per cent overall share of the NIH budget. The increasing per cent share of NIH budget allocated to CP research over time was statistically significant (mean 0.02%, 95% CI 0.02% to 0.03%, p<0.001), whereas the NHMRC change over time was close to zero (mean −0.002%, 95% CI −0.03% to 0.02%, p=0.9). The average annual per cent of the NHMRC budget allocated to CP research from 2000 to 2015 remained relatively flat at 0.5%.
Network analysis
The CPARF and NHMRC network analysis ( figure 5 ) shows a number of small groups of 3-6 researchers, based on individual grants. The largest CPARF network is three groups joined through a single high-earning researcher (number 14). The largest NHMRC network is 18 researchers joined by four key linking researchers (numbers 1, 2, 6 and 17). The network analysis indicates most CP researchers are connected through collaborations for funding. CPARF connections are broader compared with the tighter established teams obtaining NHMRC funding. Further, there are more 'islands' among the CPARF network indicating the new researchers entering the CP research field, as compared with the fewer 'islands' in the NHMRC network. Two 'islands' in the network analysis of NHMRC funding include two relatively successful researchers (numbers 8 and 9
winning four and eight grants, respectively) who are at the centre of small networks that are not linked to the main network.
DISCUSSION
In Australia, funding for CP research from the major competitive grant schemes has stabilised in the last decade. Historically, there have been irregular patterns of funding and as a consequence there is a heavy reliance on philanthropic donations to fill the gap. As there is a relatively small number of CP researchers in Australia, and because NHMRC success rates are low (currently under 15%), the annual funding awarded is sporadic. Researchers try 1 year and if they miss out, they need to resubmit the following year. 21 22 This results in irregular funding patterns for NHMRC money and subsequent impacts on maintaining research momentum. In the USA, the NIH is funding a larger number of CP researchers and their funding pattern is consistently increasing. CP needs to be a focus for the NHMRC to provide consistent funding to achieve the priorities highlighted by Australian families living with CP. 10 It is intriguing how the ups and downs in NHMRC funding are mirrored by the CPARF (with a strong correlation between the two amounts). A possible explanation for this pattern is that CP researchers submit a similar application to both agencies, with researcher's preference to obtain NHMRC funding to build their track records and CPARF picks up the 'fundable but not funded' applications, that is, NHMRC applications deemed worthy of funding but the budget was unavailable. 17 The distinction between the number of successful NHMRC research proposals that were 'new' versus resubmissions of previously unsuccessful applications could not be determined. 21 22 An alternative explanation is that NHMRC grant review panels may have contained more CP experts in some years compared with others. We examined the NHMRC peer review honour roll to see if we could quantify this for CP experts, but the data definitions were inconsistent. Another explanation is that applicants may not submit in some years because the application process takes an average of 1-2 months of research time, 21 22 and this could result in the oscillating success patterns especially as the CP community is small and well connected (figure 5). Further, funding success in the previous year may defer applications in the following year as the CP researchers focus on their current projects.
The network analysis highlights the small number of CP researchers in Australia. The limited number of 'islands' (or silos unconnected to other silos) show most CP researchers are connected through their collaborations; these networks enable research success. 4 The similar patterns for NHMRC and CPARF networks are due to the majority of CP researchers being in both groups. The CPARF works to expand networks and promote collaborations, for example, hosting the International CP Conference in 2009, and later that year appointing the world's first Professorial Chair of Cerebral Palsy. Hence, there was a peak in CPA funding in 2009, followed by a temporary drop in 2010-2011 as momentum was built for consistent funding. The small community of CP researchers adapted to being able to obtain CPARF funding and, where possible, CPARF funded what the NHMRC did not fund; both funding bodies were building research momentum for CP.
In the NHMRC funding network, there are relatively successful researchers at the centre of a small network that is not linked to the main community of CP researchers. This is surprising given that these researchers were successful in winning multiple grants. One potential explanation is the relatively common practice among Australian health and medical researchers of deliberately avoiding collaborations in order to have a qualified reviewer available to assess grant applications. The NHMRC uses strict conflict of interest rules, meaning any previous collaborators are unable to review your grant. In a small community of CP researchers, this can mean that grant applications are reviewed by researchers working in other fields who may not be able to recognise the novelty or importance of the proposed research. Another potential explanation is that the unconnected networks indicate researchers from quite different fields of research and expertise which limits collaborations across the CP research community.
These findings are an underestimate of CP funding as the search for grants was based on strict keyword search. CP researchers may have a better chance of being funded by the NHMRC if they use broader terms, such as brain injury or neonatal intensive care, rather than the specific focus on CP. With broader search terms more grants would have been identified as being relevant to CP research. Interestingly, the findings from this study identified more than double the amount of NHMRC funding as reported by the NHMRC specifically for CP. 16 This shows the value of looking through the grants summaries in detail rather than only relying on the key words. The identification of only six ARC grants for this analysis may be explained by the specific exclusion of medical and clinical research and focus of ARC funding for disabilities more generally, such as research into social inclusion, community participation and quality of life. Beyond inclusion in this study, other NHMRC grants and many more ARC grants would examine CP within a broader banner of disabilities.
The comparison between Australia and the USA is limited to competitive grants only due to the exclusion of USA philanthropic funding bodies. The analysis was limited to the competitive grants awarded by CPARF for comparison with NHMRC competitive grants. The additional philanthropic funding by CPARF is included in figure 3 as the line 'CPARF Total' to indicate the amount of additional activity funded by CPARF beyond competitive grants. There is overlap in philanthropic funding between countries as CPARF has collaborated on funding projects in the USA through PCORI and the American Academy of Cerebral Palsy and Developmental Medicine, and has initiated funding projects directly in the USA from 2016. The limitation of the analysis extends to the exclusion of other philanthropic or charitable organisations in Australia that contribute funding to people living with CP.
In the context of the economic impact of CP on the Australian community, of the $4 billion spent annually, 9 the cumulative spend in this study of $77 million represents 0.2% of the economic costs across 10 years. By way of comparison, in 2005 the global spend on cancer research as funded by government and philanthropy was estimated as 14 billion Euros and has resulted in great gains in cancer treatments. 3 In the USA, the NIH is consistently increasing the funding pattern for CP research. In Australia, the NHMRC needs to provide consistent funding to achieve the research priorities of prevention and cure of CP. Substantial future investment is needed by government and philanthropy to provide significant increased funding for CP research. A concerted global effort could further decrease the worldwide impact of this lifelong condition on families; 23 however, further research cannot occur without further funding.
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